Literature DB >> 9727883

Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients.

A Branchi1, A Rovellini, A Torri, D Sommariva.   

Abstract

OBJECTIVE: To evaluate the accuracy of LDL cholesterol calculated with Friedewald's equation in the assessment of cardiovascular risk in NIDDM patients. RESEARCH DESIGN AND METHODS: The calculation of LDL cholesterol according to Friedewald's formula was compared with the measurement of LDL cholesterol separated by ultracentrifugation in 151 NIDDM patients with fairly good metabolic control (HbA1c < or =10%) and in 405 nondiabetic subjects.
RESULTS: Measured and calculated LDL cholesterol was found to be well correlated in both diabetic (r = 0.95) and nondiabetic (r = 0.97) subjects. Compared with measured LDL cholesterol, the calculated LDL cholesterol differed by > or =10% in 34% of samples from diabetic patients and in 26% of samples from nondiabetic subjects (chi(2) = 3.885, P < 0.05). The percentage of error increased when the serum triglyceride (TG) level was > or =200 mg/dl (2.26 mmol/l) and when the ratio of VLDL cholesterol to TG was <0.20 or >0.29 in both groups of subjects. Although the percentage of error from calculated LDL cholesterol was greater in diabetic than in nondiabetic subjects because of the greater prevalence of hypertriglyceridemia in the former group, the misclassification of coronary heart disease risk, according to the cutoff points of the National Cholesterol Education Program (NCEP), was similar in the two groups (25% in diabetic and 22% in nondiabetic subjects). In both groups of patients, the misclassification of coronary heart disease risk was higher when calculation of LDL cholesterol produced values near the cutoff points.
CONCLUSIONS: Although accuracy in the estimation of LDL cholesterol is less than ideal, Friedewald's equation seems to be of value in the correct assignment of coronary heart disease risk classes in the great majority of diabetic as well as nondiabetic subjects. Caution must be exercised for subjects in whom calculated LDL cholesterol is close to the cutoff points of the NCEP guidelines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727883     DOI: 10.2337/diacare.21.9.1397

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays.

Authors:  Marcelo Jose Andrade Oliveira; Hendrick E van Deventer; Lorin M Bachmann; G Russell Warnick; Katsuyuki Nakajima; Masakasu Nakamura; Ikunosuke Sakurabayashi; Mary M Kimberly; Robert D Shamburek; William J Korzun; Gary L Myers; W Greg Miller; Alan T Remaley
Journal:  Clin Chim Acta       Date:  2013-04-27       Impact factor: 3.786

2.  Gender differences in risk factors of obese patients after cardiac rehabilitation program.

Authors:  Fatemeh Esteki Ghashghaei; Masoumeh Sadeghi; Katayoun Rabiei; Hamidreza Roohafza; Nizal Sarrafzadegan
Journal:  Iran J Nurs Midwifery Res       Date:  2012-07

3.  LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations.

Authors:  Farideh Razi; Katayoon Forouzanfar; Fatemeh Bandarian; Ensieh Nasli-Esfahani
Journal:  J Diabetes Metab Disord       Date:  2017-11-03

4.  Comparison of calculated versus directly-measured low-density lipoprotein-cholesterol: An evaluation of ten formulas for an HIV-positive population in Sub-Saharan Africa.

Authors:  Ifeyinwa Osegbe; Martin Ugonabo; Chinwe Chukwuka; Ijeoma Meka; Nnamdi Nwosu
Journal:  J Lab Physicians       Date:  2017 Apr-Jun

5.  Optimal range of triglyceride values to estimate serum low density lipoprotein cholesterol concentration in Korean adults: the Korea National Health and Nutrition Examination Survey, 2009.

Authors:  You-Cheol Hwang; Hong-Yup Ahn; In-Kyung Jeong; Kyu Jeung Ahn; Ho Yeon Chung
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

6.  The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

Authors: 
Journal:  Cardiovasc Diabetol       Date:  2004-12-01       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.